فهرست نشریات علمی دسترسی آزاد ایران

Background: Drug-induced arrhythmias pose a significant clinical challenge, with potential life-threatening complications such as cardiac arrest and sudden cardiac death. Understanding the epidemiology, implicated drugs, and clinical characteristics of drug-induced arrhythmias is crucial for optimizing patient care and improving outcomes.Methods: A retrospective cohort study involving 500 arrhythmia-diagnosed patients was conducted. Drug-induced cases were identified through meticulous medication histories. Various demographic and clinical variables were collected, and statistical analyses, including logistic regression, explored the association between drug exposure and arrhythmia development.Results: Among the 500 patients diagnosed with arrhythmias, 115 cases (23%) were attributed to pharmacological agents. Notably, amiodarone was significantly associated with arrhythmia development (p<0.001, OR=2.5, 95% CI 1.8–3.4), as were ciprofloxacin (p=0.006, OR=1.8, 95% CI 1.2–2.7), sertraline (p=0.014, OR=1.6, 95% CI 1.1–2.3), and amitriptyline (p<0.05, OR=1.6, 95% CI 1.1–2.3). Advanced age (>65 years) was significantly associated with a higher risk of drug-induced arrhythmias (OR=2.5, p<0.001), similar to a history of cardiovascular disease (OR=3.1, p<0.001). Polypharmacy (OR=2.8, p =0.002) also emerged as an independent risk factor.Conclusion: Understanding the complexity of drug-induced arrhythmias is crucial for patient care. Tailored risk assessment and management strategies are imperative to mitigate adverse outcomes associated with these arrhythmias, especially in high-risk patient populations. Incorporating personalized approaches into clinical practice can enhance patient safety and improve outcomes in individuals prone to drug-induced arrhythmias.